Loading
A phase 3 trial of camrelizumab, capecitabine, eribulin and carboplatin in triple-negative breast cancer, run by Fudan University, now recruiting.
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. is a phase 3, randomised interventional study registered as NCT05760378 by Fudan University, with a registry enrolment figure of 223 participants, started 2023-03-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: Famitinib; Camrelizumab; nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eribulin, Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Eribulin, Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Platinum agents and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/